C4 Therapeutics, Inc. (CCCC) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$2.80

From 52W high−38.12%

Volume3.11M

Market cap$355.54M

P/E (TTM)—

P/S (TTM)10.1x

Div yield—

Key dataOct 19, 2026

Open

$2.80

From 52W high

−38.12%

Volume

3.11M

Market cap

$355.54M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.6x

P/E (TTM)

—

RSI (14)

44.3

MomentumView details →

1D Return

+4.52%

YTD Return

+52.62%

SummaryUpdated Jun 1, 2026

C4 Therapeutics, Inc. (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Watertown, Massachusetts. The company went public in October 2020 and focuses on developing innovative cancer treatments using a novel approach called targeted protein degradation. C4 Therapeutics has established strategic partnerships with major pharmaceutical companies including Roche, Biogen, and Calico Life Sciences to advance its pipeline of experimental drugs through clinical trials.

Ask drillr about C4 Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.6x

EV/Sales

4.5x

P/S (TTM)

10.1x

P/B (TTM)

1.4x

ProfitabilityView details →

Gross Margin

94.86%

Net Margin

−289.44%

EBITDA Margin

−284.57%

ROE (TTM)

−41.02%

ROA (TTM)

−28.22%

Asset Turnover

0.10x

GrowthView details →

Revenue YoY

+2.33%

EPS YoY

+36.71%

FCF YoY

+2.49%

Revenue CAGR 3Y

+4.95%

EPS CAGR 3Y

+16.45%

EBITDA YoY

+6.42%

MomentumView details →

1D Return

+4.52%

YTD Return

+52.62%

1Y Return

+14.76%

RSI (14)

44.3

vs 50D SMA

−16.11%

vs 200D SMA

−7.75%

Capital & dividendView details →

Debt/Equity

0.23x

Current Ratio

5.45x

Quick Ratio

5.45x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.18

EPS Surprise

20.49%

Beats (12Q)

8/12

Next Q EPS Est

−$0.27

Avg Surprise (4Q)

12.43%

Rev Surprise

66.03%

Financials snapshotView financials →

Revenue (TTM)

35.04M

Net Income (TTM)

−101.42M

Op. CF (TTM)

−84.87M

Next earningsNov 5, 2026 →

Latest newsMore news →

C4 Therapeutics, Inc. reported a Q2 loss of $0.18 per share, beating the Zacks Consensus Estimate of a loss of $0.23 and improving from a loss of $0.37 per share a year ago.69d ago

Similar companies

Rezolute, Inc.RZLT Sirnaomics Ltd.02257.HK Galectin Therapeutics Inc.GALT Atea Pharmaceuticals, Inc.AVIR Fennec Pharmaceuticals Inc.FENC Kyverna Therapeutics, Inc.KYTX Find similar companies →

Latest newsMore news →

C4 Therapeutics, Inc. reported a Q2 loss of $0.18 per share, beating the Zacks Consensus Estimate of a loss of $0.23 and improving from a loss of $0.37 per share a year ago.69d ago